Form 4: Intra-Cellular Therapies CEO Sharon Mates Transfers Shares to Family Foundation

Sharon Mates, CEO of Intra-Cellular Therapies, reports a transfer of 190,000 shares of common stock to the Sharon Mates Family Foundation as a bona fide gift.

Summary

• This Form 4 filing reports a change in beneficial ownership of Intra-Cellular Therapies, Inc. (ITCI) stock by Sharon Mates, the company's Chairman and CEO.
• On March 26, 2025, Ms. Mates transferred 190,000 shares of ITCI common stock to the Sharon Mates Family Foundation as a gift.
• The transfer was executed at a price of $0 per share.
• Following the transaction, Ms. Mates directly owns 945,235 shares and indirectly owns 190,000 shares through the Sharon Mates Family Foundation.
• Ms. Mates disclaims beneficial ownership of the shares held by the Foundation except to the extent of her pecuniary interest therein, if any.

Sentiment

Score: 6

Explanation: The document is a standard regulatory filing, indicating a neutral sentiment. The stock transfer itself doesn't inherently suggest positive or negative implications for the company's performance.

Positives

• The transfer is reported as a bona fide gift, suggesting a philanthropic intent.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This transaction reflects a personal financial decision by the CEO and may not have a direct impact on the company's operations or financial performance.

Related Party Transactions

• The transfer of shares to the Sharon Mates Family Foundation constitutes a related party transaction.

Stakeholder Impact

• The transaction has a minimal impact on stakeholders as it is a transfer of shares from the CEO to a family foundation and does not affect the company's operations or financial position.

Key Dates

Keywords

Form 4, beneficial ownership, Intra-Cellular Therapies, ITCI, Sharon Mates, stock transfer, gift, Sharon Mates Family Foundation